Public Health & Policy >
FDA General
FDA Panel Puts Brakes on Anti-PARP Drug
WASHINGTON -- Approval of a PARP inhibitor for patients with advanced ovarian cancer should await results of an ongoing clinical trial that has the potential to answer questions about the drug's safety and efficacy, according to an FDA advisory committee that voted against immediate approval.
Jun 25, 2014
Medtronic's Infuse Moves From Operating Room to Courtroom
An investigative series by 鶹ý/Milwaukee Journal Sentinel has been tracking the spinal fusion device called Infuse in a 4-year-long series and now reports how a flawed FDA system for device approval may have led to a long string of adverse events culminating in thousands of liability suits.
May 18, 2014
Droxidopa for OH Slammed by FDA Reviewers
SILVER SPRING, Md. -- Droxidopa (Northera) is getting a second look by an FDA advisory committee for the treatment of orthostatic hypotension stemming from neurological disorders like Parkinson's disease, but an agency review doesn't look promising for approval.
Jan 13, 2014
Killing Pain: Tramadol the 'Safe' Drug of Abuse
Almost 2 decades have passed since the FDA approved tramadol as a 'safe' opioid, but the intervening years provide evidence to question that 'safe' claim, as this latest investigation by John Fauber for the Milwaukee Journal Sentinel-鶹ý revealed.
Dec 22, 2013